TY - JOUR
T1 - Polygenic prediction of atopic dermatitis improves with atopic training and filaggrin factors
AU - Arehart, Christopher H.
AU - Daya, Michelle
AU - Campbell, Monica
AU - Boorgula, Meher Preethi
AU - Rafaels, Nicholas
AU - Chavan, Sameer
AU - David, Gloria
AU - Hanifin, Jon
AU - Slifka, Mark K.
AU - Gallo, Richard L.
AU - Hata, Tissa
AU - Schneider, Lynda C.
AU - Paller, Amy S.
AU - Ong, Peck Y.
AU - Spergel, Jonathan M.
AU - Guttman-Yassky, Emma
AU - Leung, Donald Y.M.
AU - Beck, Lisa A.
AU - Gignoux, Christopher R.
AU - Mathias, Rasika A.
AU - Barnes, Kathleen C.
N1 - Funding Information:
Funding for this work was provided by the National Institutes of Health / National Institute of Allergy and Infectious Disease (grant U19 AI117673 ), the Atopic Dermatitis Research Network , and the Oregon National Primate Research Center (grant 8P51 OD011092 [to M.K.S.]).
Publisher Copyright:
© 2021
PY - 2022/1
Y1 - 2022/1
N2 - Background: While numerous genetic loci associated with atopic dermatitis (AD) have been discovered, to date, work leveraging the combined burden of AD risk variants across the genome to predict disease risk has been limited. Objectives: This study aims to determine whether polygenic risk scores (PRSs) relying on genetic determinants for AD provide useful predictions for disease occurrence and severity. It also explicitly tests the value of including genome-wide association studies of related allergic phenotypes and known FLG loss-of-function (LOF) variants. Methods: AD PRSs were constructed for 1619 European American individuals from the Atopic Dermatitis Research Network using an AD training dataset and an atopic training dataset including AD, childhood onset asthma, and general allergy. Additionally, whole genome sequencing data were used to explore genetic scoring specific to FLG LOF mutations. Results: Genetic scores derived from the AD-only genome-wide association studies were predictive of AD cases (PRSAD: odds ratio [OR], 1.70; 95% CI, 1.49-1.93). Accuracy was first improved when PRSs were built off the larger atopy genome-wide association studies (PRSAD+: OR, 2.16; 95% CI, 1.89-2.47) and further improved when including FLG LOF mutations (PRSAD++: OR, 3.23; 95% CI, 2.57-4.07). Importantly, while all 3 PRSs correlated with AD severity, the best prediction was from PRSAD++, which distinguished individuals with severe AD from control subjects with OR of 3.86 (95% CI, 2.77-5.36). Conclusions: This study demonstrates how PRSs for AD that include genetic determinants across atopic phenotypes and FLG LOF variants may be a promising tool for identifying individuals at high risk for developing disease and specifically severe disease.
AB - Background: While numerous genetic loci associated with atopic dermatitis (AD) have been discovered, to date, work leveraging the combined burden of AD risk variants across the genome to predict disease risk has been limited. Objectives: This study aims to determine whether polygenic risk scores (PRSs) relying on genetic determinants for AD provide useful predictions for disease occurrence and severity. It also explicitly tests the value of including genome-wide association studies of related allergic phenotypes and known FLG loss-of-function (LOF) variants. Methods: AD PRSs were constructed for 1619 European American individuals from the Atopic Dermatitis Research Network using an AD training dataset and an atopic training dataset including AD, childhood onset asthma, and general allergy. Additionally, whole genome sequencing data were used to explore genetic scoring specific to FLG LOF mutations. Results: Genetic scores derived from the AD-only genome-wide association studies were predictive of AD cases (PRSAD: odds ratio [OR], 1.70; 95% CI, 1.49-1.93). Accuracy was first improved when PRSs were built off the larger atopy genome-wide association studies (PRSAD+: OR, 2.16; 95% CI, 1.89-2.47) and further improved when including FLG LOF mutations (PRSAD++: OR, 3.23; 95% CI, 2.57-4.07). Importantly, while all 3 PRSs correlated with AD severity, the best prediction was from PRSAD++, which distinguished individuals with severe AD from control subjects with OR of 3.86 (95% CI, 2.77-5.36). Conclusions: This study demonstrates how PRSs for AD that include genetic determinants across atopic phenotypes and FLG LOF variants may be a promising tool for identifying individuals at high risk for developing disease and specifically severe disease.
KW - Atopic dermatitis
KW - allergic disease
KW - atopic march
KW - disease prediction
KW - filaggrin
KW - genetic architecture
KW - genetic predisposition
KW - polygenic risk score
UR - http://www.scopus.com/inward/record.url?scp=85110418511&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2021.05.034
DO - 10.1016/j.jaci.2021.05.034
M3 - Article
C2 - 34111454
AN - SCOPUS:85110418511
SN - 0091-6749
VL - 149
SP - 145
EP - 155
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 1
ER -